BRAF tyrosine kinase inhibitors like Vemurafenib and Dabrafenib effectively inhibit the downstream activated MAPK (mitogen-activated protein kinase) pathway and have shown improved disease control rates (CR + PR + SD) of up to 92%, significantly prolonged progression and overall survival compared to chemotherapy in extracranial metastatic melanoma [23, 42]. The gene discussed is BRAF; the disease is metastatic melanoma.